Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Long-term therapeutic effects of mesenchymal stem cells compared to dexamethasone on recurrent experimental autoimmune uveitis of rats.

Zhang L, Zheng H, Shao H, Nian H, Zhang Y, Bai L, Su C, Liu X, Dong L, Li X, Zhang X.

Invest Ophthalmol Vis Sci. 2014 Aug 14;55(9):5561-71. doi: 10.1167/iovs.14-14788.

2.

Mesenchymal stem cells ameliorate experimental autoimmune uveoretinitis by comprehensive modulation of systemic autoimmunity.

Zhang X, Ren X, Li G, Jiao C, Zhang L, Zhao S, Wang J, Han ZC, Li X.

Invest Ophthalmol Vis Sci. 2011 May 16;52(6):3143-52. doi: 10.1167/iovs.10-6334.

PMID:
21296818
3.

Mesenchymal stem cells induce functionally active T-regulatory lymphocytes in a paracrine fashion and ameliorate experimental autoimmune uveitis.

Tasso R, Ilengo C, Quarto R, Cancedda R, Caspi RR, Pennesi G.

Invest Ophthalmol Vis Sci. 2012 Feb 16;53(2):786-93. doi: 10.1167/iovs.11-8211. Print 2012 Feb.

4.

The effect of mesenchymal stem cells on dynamic changes of T cell subsets in experimental autoimmune uveoretinitis.

Li G, Yuan L, Ren X, Nian H, Zhang L, Han ZC, Li X, Zhang X.

Clin Exp Immunol. 2013 Jul;173(1):28-37. doi: 10.1111/cei.12080.

5.

Systemic transplantation of allogenic fetal membrane-derived mesenchymal stem cells suppresses Th1 and Th17 T cell responses in experimental autoimmune myocarditis.

Ohshima M, Yamahara K, Ishikane S, Harada K, Tsuda H, Otani K, Taguchi A, Miyazato M, Katsuragi S, Yoshimatsu J, Kodama M, Kangawa K, Ikeda T.

J Mol Cell Cardiol. 2012 Sep;53(3):420-8. doi: 10.1016/j.yjmcc.2012.06.020. Epub 2012 Jul 13.

PMID:
22796574
6.

Effects of bucillamine and antigen-presenting cells in experimental autoimmune uveitis in rats.

Sawa K, Mochizuki M.

Jpn J Ophthalmol. 1997 Nov-Dec;41(6):388-95.

PMID:
9509306
7.

Therapeutic effects of mesenchymal stem cells administered at later phase of recurrent experimental autoimmune uveitis.

Zhao PT, Zhang LJ, Shao H, Bai LL, Yu B, Su C, Dong LJ, Liu X, Li XR, Zhang XM.

Int J Ophthalmol. 2016 Oct 18;9(10):1381-1389. eCollection 2016.

8.

Spontaneously relapsing-remitting experimental autoimmune uveitis in rats allows successful therapeutic oral tolerance induction in ongoing disease.

Huber A, Diedrichs-Möhring M, Wildner G.

Mol Immunol. 2015 Feb;63(2):215-26. doi: 10.1016/j.molimm.2014.07.009. Epub 2014 Jul 30.

PMID:
25085538
9.

Amelioration of experimental autoimmune uveoretinitis with nuclear factor-{kappa}B Inhibitor dehydroxy methyl epoxyquinomicin in mice.

Iwata D, Kitaichi N, Miyazaki A, Iwabuchi K, Yoshida K, Namba K, Ozaki M, Ohno S, Umezawa K, Yamashita K, Todo S, Ishida S, Onoé K.

Invest Ophthalmol Vis Sci. 2010 Apr;51(4):2077-84. doi: 10.1167/iovs.09-4030. Epub 2009 Nov 11.

PMID:
19907030
10.

Novel IL27p28/IL12p40 cytokine suppressed experimental autoimmune uveitis by inhibiting autoreactive Th1/Th17 cells and promoting expansion of regulatory T cells.

Wang RX, Yu CR, Mahdi RM, Egwuagu CE.

J Biol Chem. 2012 Oct 19;287(43):36012-21. doi: 10.1074/jbc.M112.390625. Epub 2012 Aug 30.

11.

[Translational research with experimental autoimmune uveoretinitis (EAU)].

Usui M.

Nippon Ganka Gakkai Zasshi. 2007 Mar;111(3):137-58; discussion 159. Review. Japanese.

PMID:
17402560
12.

Effector T cells driving monophasic vs. relapsing/remitting experimental autoimmune uveitis show unique pathway signatures.

von Toerne C, Sieg C, Kaufmann U, Diedrichs-Möhring M, Nelson PJ, Wildner G.

Mol Immunol. 2010 Nov-Dec;48(1-3):272-80. doi: 10.1016/j.molimm.2010.07.017. Epub 2010 Aug 19.

PMID:
20727594
13.

Cytokines in autoimmune uveitis.

Horai R, Caspi RR.

J Interferon Cytokine Res. 2011 Oct;31(10):733-44. doi: 10.1089/jir.2011.0042. Epub 2011 Jul 25. Review.

14.
15.

Mesenchymal stem/stromal cells precondition lung monocytes/macrophages to produce tolerance against allo- and autoimmunity in the eye.

Ko JH, Lee HJ, Jeong HJ, Kim MK, Wee WR, Yoon SO, Choi H, Prockop DJ, Oh JY.

Proc Natl Acad Sci U S A. 2016 Jan 5;113(1):158-63. doi: 10.1073/pnas.1522905113. Epub 2015 Dec 22.

16.

Amelioration of experimental autoimmune uveitis by leflunomide in Lewis rats.

Fang CB, Zhou DX, Zhan SX, He Y, Lin Z, Huang C, Li J.

PLoS One. 2013 Apr 23;8(4):e62071. doi: 10.1371/journal.pone.0062071. Print 2013.

17.

A new small molecule for treating inflammation and chorioretinal neovascularization in relapsing-remitting and chronic experimental autoimmune uveitis.

Diedrichs-Möhring M, Leban J, Strobl S, Obermayr F, Wildner G.

Invest Ophthalmol Vis Sci. 2014 Dec 16;56(2):1147-57. doi: 10.1167/iovs.14-15518.

PMID:
25515581
18.

CTLA4-Ig suppresses development of experimental autoimmune uveitis in the induction and effector phases: Comparison with blockade of interleukin-6.

Iwahashi C, Fujimoto M, Nomura S, Serada S, Nakai K, Ohguro N, Nishida K, Naka T.

Exp Eye Res. 2015 Nov;140:53-64. doi: 10.1016/j.exer.2015.08.012. Epub 2015 Aug 20.

PMID:
26297802
19.

Inhibitory effects of tetrandrine on bovine serum albumin-induced uveitis in rabbits.

Xiao J, Wu S, Wang Y, Li J, Zhang S.

J Ocul Pharmacol. 1993 Summer;9(2):151-6.

PMID:
8345287
20.

Inducible Costimulator Gene-Transduced Bone Marrow-Derived Mesenchymal Stem Cells Attenuate the Severity of Acute Graft-Versus-Host Disease in Mouse Models.

Yang D, Wang LP, Zhou H, Cheng H, Bao XC, Xu S, Zhang WP, Wang JM.

Cell Transplant. 2015;24(9):1717-31. doi: 10.3727/096368914X684592. Epub 2014 Sep 8.

PMID:
25203502

Supplemental Content

Support Center